{"pub": "morningstar", "url": "https://morningstar.com/news/dow-jones/201910089441/health-care-down-on-flight-from-risk-health-care-roundup", "downloaded_at": "2019-10-09 00:21:41.848651+00:00", "title": "Health Care Down On Flight From Risk \u2014 Health Care Roundup", "language": "en", "text": "Health-care companies fell as biotech and cannabis stocks were hurt by a flight from risk.\n\nClovis Oncology shares fell after analysts at brokerage Goldman Sachs cut their price target on the cancer-drug developer. Medical-testing company Qiagen saw shares fell after it cut its quarterly growth estimate and said its chief executive would step down.\n\nRivals in the scientific supplies niche such as Thermo Fisher Scientific and Boston Scientific fell in sympathy. MedMen Enterprises shares fell after the company said it has terminated its deal to buy PharmaCann, as the cannabis company said it would focus on retail business and California market rather than completing the $682 million acquisition.\n\nThe U.S. Food and Drug Administration granted commercial approval to Clinuvel's Scenesse, or afamelanotide, for use by patients suffering from a rare sensitivity sunlight.\n\nWrite to Rob Curran at rob.curran@dowjones.com\n\n(END) Dow Jones Newswires\n\nOctober 08, 2019 17:10 ET (21:10 GMT)\n\nCopyright (c) 2019 Dow Jones & Company, Inc.", "description": "", "authors": [], "top_image": "https://morningstar.com/assets/img/30241a1.png", "published_at": "2019-10-08"}